http://www.advfn.com/nasdaq/rss.asp?symbol=VVUS Vivus Company Newsfeed en Wed, 01 May 2013 09:38:53 EDT Wed, 01 May 2013 09:38:53 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=57394976&headline=first-manhattan-to-continue-with-board-overhaul-push-at-vivus http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=57394976&headline=first-manhattan-to-continue-with-board-overhaul-push-at-vivus <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Dissident Vivus Inc. (VVUS) shareholder First Manhattan Co. indicated it will continue pushing Vivus to overhaul its entire board, despite the recent appointment by the drug maker of a seventh member. </p> <p> On Tuesday, Vivus said it had appointed... Wed, 01 May 2013 09:38:53 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=56461496&headline=u-s-hot-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=56461496&headline=u-s-hot-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies with shares expected to actively trade in Tuesday's session are RadioShack Corp. (RSH), Assisted Living Concepts Inc. (ALC) and Caesars Entertainment Corp. (CZR). </p> <p> RadioShack reported its fourth straight quarterly loss Tuesday as the consumer electronics... Tue, 26 Feb 2013 09:07:23 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=55730390&headline=vivuss-free-promotion-lifts-prescriptions-for-diet-drug http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=55730390&headline=vivuss-free-promotion-lifts-prescriptions-for-diet-drug <div class='newsbody'><pre> By Joseph Walker </pre> <p> Vivus Inc. (VVUS) reported a 67% increase in prescriptions for the weight-loss drug Qsymia, helped by a promotion that began in November to give patients the first two weeks of their prescriptions for free. </p> <p> The jump in prescriptions may... Mon, 07 Jan 2013 11:14:02 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=55330944&headline=fda-approves-highest-number-of-new-drugs-since-2004 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=55330944&headline=fda-approves-highest-number-of-new-drugs-since-2004 <div class='newsbody'><pre> By Jennifer Corbett Dooren </pre> <p> WASHINGTON--The U.S. Food and Drug Administration has approved the most new drugs in eight years--partly reflecting improvements by the pharmaceutical industry in moving experimental drugs out of company pipelines. </p> <p> Through the... Wed, 05 Dec 2012 15:02:25 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=53531685&headline=vivus-shares-drop-amid-report-questioning-diet-drugs-prospects http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=53531685&headline=vivus-shares-drop-amid-report-questioning-diet-drugs-prospects <div class='newsbody'><pre> By Peter Loftus </pre> <p> Shares of Vivus Inc. (VVUS) fell 11% Thursday after a stock-research website raised questions about prospects for the drug maker's newly approved weight-loss drug Qsymia. </p> <p> Citron Research, which holds positions in some of the stocks it covers... Thu, 19 Jul 2012 17:15:53 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=52191259&headline=fda-approves-stendra-for-erectile-dysfunction http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=52191259&headline=fda-approves-stendra-for-erectile-dysfunction <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- The Food and Drug Administration Friday approved a new drug from Vivus Inc. (VVUS) to treat erectile dysfunction. </p> <p> The approval of the drug, Stendra, is the first product approval... Fri, 27 Apr 2012 14:44:08 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=51828328&headline=fda-panel-recommends-more-stringent-clinical-trials-for-obesity http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=51828328&headline=fda-panel-recommends-more-stringent-clinical-trials-for-obesity <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> A Food and Drug Administration panel Thursday recommended more stringent clinical trials for obesity drugs to better assess heart risks. </p> <p> The FDA convened a two-day advisory committee meeting to discuss the... Thu, 29 Mar 2012 17:40:15 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=51768413&headline=us-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=51768413&headline=us-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies with shares expected to actively trade in Monday's session are Armstrong World Industries Inc. (AWI), Weatherford International Ltd. (WFT) and Vivus Inc. (VVUS). </p> <p> Armstrong declared a special dividend of $8.55 a share as the company joined a handful... Mon, 26 Mar 2012 09:12:54 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=51246001&headline=fda-vivus-weight-loss-drug-effective-but-has-safety-concerns http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=51246001&headline=fda-vivus-weight-loss-drug-effective-but-has-safety-concerns <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- The Food and Drug Administration said Vivus Inc.'s (VVUS) obesity drug Qnexa was effective at helping people lose weight but raised concerns about possible long-term side effects such as... Fri, 17 Feb 2012 09:25:46 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=50668500&headline=us-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=50668500&headline=us-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies whose shares are expected to actively trade in Monday's session are Idenix Pharmaceuticals Inc. (IDIX), Inhibitex Inc. (INHX) and GlaxoSmithKline PLC (GSK, GSK.LN). </p> <p> Idenix surged 44% to $10.16 in recent premarket trading in the wake of fellow Hepatitis... Mon, 09 Jan 2012 09:07:39 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46742909&headline=correct-fda-strengthens-topamax-warning-on-evidence-of-birth http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46742909&headline=correct-fda-strengthens-topamax-warning-on-evidence-of-birth <div class='newsbody'><p> ("FDA Strengthens Topamax Warning On Evidence Of Birth Defects," published at 10:43 a.m. EST, misstated the prevalence rate of birth defects among infants exposed to topiramate. A corrected version follows.) </p> <p> DOW JONES NEWSWIRES </p> <p> The U.S. Food and Drug Administration... Fri, 04 Mar 2011 13:06:49 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46740841&headline=fda-strengthens-topamax-warning-on-evidence-of-birth-defects http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46740841&headline=fda-strengthens-topamax-warning-on-evidence-of-birth-defects <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> The U.S. Food and Drug Administration said it will strengthen warnings on the anti-migraine treatment Topamax and its generic equivalents after new data suggested a higher risk for cleft palates in babies born to women taking the drug. </p> <p> The... Fri, 04 Mar 2011 11:13:07 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46511693&headline=orexigen-financial-chief-cooper-resigns http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46511693&headline=orexigen-financial-chief-cooper-resigns <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Orexigen Therapeutics Inc. (OREX) said its chief financial officer is stepping down after four years as the biopharmaceutical company named a strategy executive to replace him on an interim basis. </p> <p> Financial chief and treasurer Graham Cooper... Thu, 17 Feb 2011 09:07:03 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46261403&headline=diet-drug-decision-shows-why-drug-makers-have-kept-distance http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=46261403&headline=diet-drug-decision-shows-why-drug-makers-have-kept-distance <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- The U.S. Food and Drug Administration's rejection of the latest diet pill shows the high bar for such treatments, proves why large drug makers have kept their distance from the space and leaves the nation... Tue, 01 Feb 2011 16:14:46 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45830949&headline=approvals-of-new-drugs-down-in-2010-vs-2009-2008 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45830949&headline=approvals-of-new-drugs-down-in-2010-vs-2009-2008 <div class='newsbody'><p> By Jennifer Corbett Dooren </p> <p> Of DOW JONES NEWSWIRES </p> <p> WASHINGTON -(Dow Jones)- The number of new drugs approved by the Food and Drug Administration in 2010 looks to be about 21, a relatively low figure that shows the pharmaceutical industry hasn't yet escaped its... Thu, 30 Dec 2010 17:22:24 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45722021&headline=vivus-files-european-market-application-for-diet-pill-qnexa http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45722021&headline=vivus-files-european-market-application-for-diet-pill-qnexa <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Vivus Inc. (VVUS) filed a marketing application with the European Medicines Agency for its Qnexa weight-loss drug. </p> <p> The EMA's review could result in marketing authorization in all 27 European... Mon, 20 Dec 2010 07:47:21 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45643514&headline=vivus-submits-qnexa-response-to-fda-meeting-set-for-january http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45643514&headline=vivus-submits-qnexa-response-to-fda-meeting-set-for-january <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Vivus Inc. (VVUS) said it has responded to the U.S. Food and Drug Administration's concerns about obesity drug Qnexa and has set a meeting for late January to discuss the company's latest effort to win its approval. </p> <p> The disclosure follows... Tue, 14 Dec 2010 07:48:37 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45569938&headline=orexigen-fda-panel-vote-provides-hope-for-approval-other-cos http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45569938&headline=orexigen-fda-panel-vote-provides-hope-for-approval-other-cos <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- A U.S. Food and Drug Administration panel's positive recommendation of Orexigen Therapeutics Inc.'s (OREX) weight-loss drug Contrave increases the likelihood for approval and provides hope for Arena Pharmaceuticals... Wed, 08 Dec 2010 11:02:12 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45147545&headline=correct-arena-eisai-obesity-drug-shows-success-in-diabetes http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45147545&headline=correct-arena-eisai-obesity-drug-shows-success-in-diabetes <div class='newsbody'><p> ("Arena, Eisai Obesity Drug Shows Success In Diabetes Patients" at 3:05 a.m. EST, incorrectly reported that lorcaserin showed improvements in fasting glucose, HDL cholesterol and triglycerides, based on a previous version of a company press release. A corrected version follows:... Tue, 09 Nov 2010 08:49:11 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45139438&headline=arena-eisai-obesity-drug-shows-success-in-diabetes-patients http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VVUS&article=45139438&headline=arena-eisai-obesity-drug-shows-success-in-diabetes-patients <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Arena Pharmaceuticals Inc. (ARNA) and Eisai Co.'s (ESALY, 4523.TO) weight-loss drug lorcaserin helped diabetic patients lose weight, according to recent data, but it is unclear if the findings are strong... Tue, 09 Nov 2010 03:34:42 EST